Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. It is also developing ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ITCI
CUSIPN/A
Phone646-440-9333
Debt
Debt-to-Equity RatioN/A
Current Ratio22.55
Quick Ratio22.55
Price-To-Earnings
Trailing P/E Ratio-8.50
Forward P/E Ratio-5.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$250,000.00
Price / Sales3,951.53
Cash FlowN/A
Price / CashN/A
Book Value$8.33 per share
Price / Book2.17
Profitability
EPS (Most Recent Fiscal Year)($2.12)
Net Income$-97,770,000.00
Net Margins-39,745.53%
Return on Equity-27.67%
Return on Assets-26.57%
Miscellaneous
Employees49
Outstanding Shares54,700,000
Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions
What is Intra-Cellular Therapies' stock symbol?
Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."
How were Intra-Cellular Therapies' earnings last quarter?
Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.01. Intra-Cellular Therapies had a negative net margin of 39,745.53% and a negative return on equity of 27.67%. View Intra-Cellular Therapies' Earnings History.
When is Intra-Cellular Therapies' next earnings date?
What price target have analysts set for ITCI?
10 brokers have issued twelve-month target prices for Intra-Cellular Therapies' stock. Their predictions range from $24.00 to $36.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $29.10 in the next twelve months. View Analyst Ratings for Intra-Cellular Therapies.
What are Wall Street analysts saying about Intra-Cellular Therapies stock?
Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:
- 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (5/8/2018)
- 2. Cantor Fitzgerald analysts commented, "Lumateperone NDA filing still expected in mid-2018. We view the pre- NDA meeting (and what may be said thereafter), the actual filing and the FDA acceptance of it (presumably) as minor events that are expected and not stock moving." (3/1/2018)
- 3. SunTrust Banks, Inc. analysts commented, "Meeting with FDA could help identify the path forward for ralinepag. On the 3Q17 results conference call, management commented that the company will seek a meeting with the FDA to determine the pivotal development plan for ralinepag. Specific timing of the meeting is pending FDA scheduling but management laid out their views on the drug candidate’s development program. Key considerations include 1) accelerating time to market, 2) maximizing the breadth and scope of label, 3) raising physician awareness of the compound and 4) comparing ralinepag with other available treatments." (11/8/2017)
Who are some of Intra-Cellular Therapies' key competitors?
Some companies that are related to Intra-Cellular Therapies include Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Horizon Pharma (HZNP), Blueprint Medicines (BPMC), Portola Pharmaceuticals (PTLA), Ascendis Pharma A/S (ASND), TESARO (TSRO), The Medicines (MDCO), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK) and Clovis Oncology (CLVS).
Who are Intra-Cellular Therapies' key executives?
Intra-Cellular Therapies' management team includes the folowing people:
- Dr. Sharon Mates Ph.D., Co-Founder, Chairman, CEO & Pres (Age 65)
- Mr. Lawrence J. Hineline CPA, VP of Fin., CFO, Treasurer & Assistant Sec. (Age 62)
- Dr. Robert E. Davis Ph.D., Sr. VP & Chief Scientific Officer (Age 67)
- Mr. Michael I. Halstead J.D., Sr. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 45)
- Dr. Kimberly E. Vanover Ph.D., Sr. VP of Clinical Devel. (Age 52)
Has Intra-Cellular Therapies been receiving favorable news coverage?
News stories about ITCI stock have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intra-Cellular Therapies earned a media sentiment score of 0.16 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.82 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Intra-Cellular Therapies' major shareholders?
Intra-Cellular Therapies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.86%), Wasatch Advisors Inc. (3.44%), PointState Capital LP (3.42%), Dimensional Fund Advisors LP (2.19%), Columbus Circle Investors (1.02%) and Northern Trust Corp (0.90%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.
Which institutional investors are selling Intra-Cellular Therapies stock?
ITCI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., JPMorgan Chase & Co., Dimensional Fund Advisors LP, C WorldWide Group Holding A S, DekaBank Deutsche Girozentrale, GSA Capital Partners LLP and Federated Investors Inc. PA. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.
Which institutional investors are buying Intra-Cellular Therapies stock?
ITCI stock was purchased by a variety of institutional investors in the last quarter, including PointState Capital LP, Columbus Circle Investors, Hsbc Holdings PLC, Engineers Gate Manager LP, ETF Managers Group LLC, D.A. Davidson & CO., Atlantic Trust Group LLC and New York State Common Retirement Fund. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies.
How do I buy shares of Intra-Cellular Therapies?
Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intra-Cellular Therapies' stock price today?
One share of ITCI stock can currently be purchased for approximately $18.14.
How big of a company is Intra-Cellular Therapies?
Intra-Cellular Therapies has a market capitalization of $1.02 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-97,770,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Intra-Cellular Therapies employs 49 workers across the globe.
How can I contact Intra-Cellular Therapies?
Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]
MarketBeat Community Rating for Intra-Cellular Therapies (ITCI)
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
